A highly sensitive liquid chromatography electrospray ionization mass spectrometry method for quantification of TMA, TMAO and creatinine in mouse urine by Veeravalli, S et al.
MethodsX 4 (2017) 310–319
Contents lists available at ScienceDirect
MethodsX
journal homepage: www.elsevier.com/locate/mexMethod ArticleA highly sensitive liquid chromatography
electrospray ionization mass spectrometry
method for quantiﬁcation of TMA, TMAO and
creatinine in mouse urine
Sunil Veeravallia, Kersti Karub, Ian R. Phillipsa,c,
Elizabeth A. Shepharda,*
a Institute of Structural and Molecular Biology, University College London, London, UK
bMass Spectrometry Facility, Department of Chemistry, University College London, London, UK
c School of Biological and Chemical Sciences, Queen Mary University of London, London, UK
G R A P H I C A L A B S T R A C TA B S T R A C T
Our method describes the quantiﬁcation in mouse urine of trimethylamine (TMA), trimethylamine N-oxide
(TMAO) and creatinine. The method combines derivatization of TMA, with ethyl bromoacetate, and LC
chromatographic separation on an ACE C18 column. The efﬂuent was continuously electrosprayed into the linear
ion trap mass spectrometer (LTQ), which operated in selective ion monitoring (SIM) modes set for targeted
analytes and their internal standards (IS). All validation parameters were within acceptable ranges of analytical
method validation guidelines. Intra- and inter-day assay precision and accuracy coefﬁcients of variation were
<3.1%, and recoveries for TMA and TMAO were 97–104%. The method developed uses a two-step procedure.
Firstly, TMA and TMAO are analyzed without a puriﬁcation step using a 5-min gradient cap-LC- SIMs analysis,
then creatinine is analyzed using the same experimental conditions. The method is robust, highly sensitive,
reproducible and has the high-throughput capability of detecting TMA, TMAO and creatinine at on-column* Corresponding author.
E-mail address: e.shephard@ucl.ac.uk (E.A. Shephard).
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S. Veeravalli et al. /MethodsX 4 (2017) 310–319 311concentrations as low as 28pg/mL, 115pg/mL and 1ng/mL, respectively. The method is suitable for analysis of
TMA, TMAO and creatinine in both male and female mouse urine.
The key beneﬁts of the method are:
 The small sample volume of urine required, which overcomes the difﬁculties of collecting sufﬁcient volumes of
urine at deﬁned times.
 No sample pre-treatment is necessary.
 The quantiﬁcation of TMA, TMAO and creatinine using the same cap-LC- [54_TD$DIFF]MS method.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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Background
Inmammals, trimethylamine (TMA) [56_TD$DIFF]is liberated by the action of gut bacteria on a number of dietary
components [57_TD$DIFF] 1–4]. The released TMA is rapidly absorbed and converted in the liver to trimethylamine
N-oxide (TMAO) in a reaction catalysed by the enzyme FMO3 [5]. TMA and TMAO are excreted in urine
[6]. The conversion of TMA to TMAO is impaired in individuals with the rare disorder primary
trimethylaminuria [7]. Consequently, such individuals excrete large amounts of TMA in urine. The
condition is caused by mutations in the FMO3 gene [5,8]. Certain common polymorphic variants of
FMO3, when present in the homozygous state, can result in mild or transient trimethylaminuria [9].
Changes in the amounts of TMAor TMAO in biological samples have also been reported for disorders of
the liver [10] and kidney [11–13] and for pancreatic cancer [14]. In addition, [58_TD$DIFF] increased production of
TMAO has also been implicated as a risk factor in cardiovascular disease [15]. Measurements of TMA
and TMAO in bodily ﬂuids such as plasma or urine are therefore being used increasingly to monitor
changes in disease state and/or as an indication of altered gut microbial action.
Severalmethods have been reported for the determination of TMA and TMAO in human urine,most
of which have been developed for the diagnosis of trimethylaminuria. These include gas
chromatography (GC) [16,17], high-performance liquid chromatography (HPLC) [18], proton nuclear
magnetic resonance spectroscopy (1H- [59_TD$DIFF]NMR) [19–21], fast atom bombardment mass spectrometry
(FAB-MS) [22], matrix-assisted laser desorption/ionization with time-of-ﬂight MS (MALDI-TOF-MS)
[23] [60_TD$DIFF]and stable isotope dilution (SID)-LC-MRM-MS [24].
The mouse is often used as a model organism for basic and preclinical research. Collection of urine
for metabolite analyses has the advantage of being non-invasive. However, urine cannot be collected
‘on demand’ from an experimental animal. Therefore, we optimised amethod for the quantiﬁcation of
TMA and TMAO in mouse urine when sample size is limited and time of collection is important.
Johnson [25] developed a ﬂow injection ESI-MS/MS method in which TMA is derivatized with ethyl
bromoacetate to form betaine bromide, which improves ionization efﬁciency using ESI conditions.
Thismethod does not include a chromatographic separation step, the absence of which could lead to a
suppression of analyte ionization under ESI conditions due tomatrix effects. Matrix effects could pose
a problemwhen analyzing male mouse urine, because male mice excrete large amounts of protein in
their urine, which is bound by volatile ligands [26]. This is thought to be a mechanism by which male
mice are able to extend the longevity of various scent markers.
To address the high variability in the concentration of urine samples [61_TD$DIFF]among individuals, the
concentrations of compounds in urine are reported after normalization to creatinine concentration
[27]. Johnsonmeasured creatinine concentration in human urine using an enzymaticmethod [25]. Lee
et al. [28] used the derivatization method of Johnson for TMA and TMAO quantiﬁcation and added a
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urine volumes of 25mL.
Our aimwas to develop a sensitive and reproduciblemethod, based on themethods of Johnson [25]
and Lee et al. [28], that would allow quantiﬁcation of TMA, TMAO and creatinine from only a drop of
mouse urine. Lee et al. [28] included a chromatographic separation step which we chose to include
because of the high protein concentration in male mouse urine, as mentioned above. To improve
analyte separation, selectivity and sensitivity a modiﬁed gradient and a C18 column were used. This
column is longer and has a smaller pore size than that used by Lee et al. [28]. We used a ﬂow rate of
200mL/min, [62_TD$DIFF]selective ion monitoring (SIM) and a different instrumentation set-up, which are
described below. A further modiﬁcation of the method of Lee et al. [28] was the use of 2H9-TMA and
2H9-TMAO, as the internal standards for TMA and TMAO, instead of terfenadine. The method we
describewas validated according to Guidelines for Bioanalytical Method Validation of the US FDA [29]
and of the European Medicines Agency (EMEA) [30].
Materials
TMA HCl (98% purity), creatinine (99% purity) and ethyl bromoacetate (98% purity) were obtained
from Fischer Scientiﬁc (Loughborough, Leicestershire, UK). TMAO, acetaminophen, water (HPLC
grade), formic acid (98% purity), ammonium hydroxide (99% purity) and ammonium formate were
purchased from Sigma-Aldrich (Gillingham, Dorset, UK). Trimethyl-d9-amine HCl (2H9-TMA) was
obtained fromQmx Laboratories (Thaxted, Essex, UK). Trimethyl-d9-amine [7_TD$DIFF]N-oxide (98% purity) (2H9-
TMAO) was purchased from Cambridge Isotope (Andover, MA, USA). Acetonitrile Hipersolv chroma,
isocratic for HPLC, and anion-cation exchange (ACE) C18 (2.1mm x 150mm, 3mm) column were
purchased from VWR International (Lutterworth, Leicestershire, UK).
Urine sample collection
Althoughmetabolic cages are sometimes used for a continuous and complete 24-h urine collection,
housing in metabolic cages can cause stress to animals, evaporation of urine and contamination of
urine with food and/or feces. Male and female C57BL/6J mice were bred in-house at UCL. Male and
female CD-1 mice were purchased from Charles River (Margate, Kent, UK) and allowed to acclimatize
for 14days before collection of urine. Micewere housed in an environmentally controlled roomwith a
12-h light/dark cycle and fed [63_TD$DIFF]on a standard chow diet (Teklad Global 18% Protein Rodent Diet, Harlan
Laboratories, Inc., Madison, WI, USA) with free access to water. Mice were 10 weeks old at the time of
urine collection. Urine was obtained by gently holding a mouse and allowing it to urinate onto Saran
wrap; drops of urine were collected using a micropipette [31]. Samples were collected between 10 a.
m. and 12 noon (a.m. samples) or 2p.m and 4p.m (p.m. samples) and were stored at 80 C until use.
Animal procedures were carried out in accordance with the UK Animal Scientiﬁc Procedures Act and
with local ethics committee approval and appropriate UK Home Ofﬁce Licenses.
Preparation of standards and urine samples for TMA and TMAO analysis
Working standards contained both TMAand TMAO, each at 7.8,15.6, 31.3, 62.5,125, 250 and 500ng/
mL in water. For aqueous standard solutions, 20mL of each TMA-TMAO working standard was mixed
with 5mL of water. Urine samples were thawed to room temperature and 5mL mixed with 20mL of
water. Derivatization reaction of TMA was as described by Johnson [25]. Brieﬂy, to 25mL of the
prepared aqueous standards and urine samples,1mL 2H9-TMA (1mg/mL), 2mL of 2H9-TMAO (1mg/mL),
1mL of concentrated ammonia and 30mL of ethyl bromoacetate (20mg/mL in acetonitrile) were
added. Samples were incubated for 30min at room temperature. The reaction was stopped by the
addition of 1mL of 50% acetonitrile, 0.025% formic acid in water. Samples were centrifuged at
15,700 g for 3min at room temperature. Supernatant (100mL) was diluted to a ﬁnal volume of 1mL
with 50% acetonitrile, 0.025% formic acid inwater. Concentrations of both derivatized TMA and TMAO
in these aqueous standards [64_TD$DIFF]were 15, 30, 59, 118, 236, 472 and 944pg/mL. Twenty mL of an aqueous
standard or of a urine sample were injected onto a C18 column.
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Stock solutions of creatinine (1mg/mL) and acetaminophen (20mg/mL) were prepared inwater and
ethanol, respectively, and stored at 20 C. Working standards of creatinine (0.24, 0.98, 3.91, 15.62,
62.5, 250 and 1000ng/mL) were prepared in 0.1% formic acid in water. To 16mL of each working
standard of creatinine was added 1mL of acetaminophen (20mg/mL in ethanol) and 983mL of 0.1%
formic acid. Final concentrations of creatinine standards were 3.9, 15.6, 62.5, 250, 1000, 4000 and
16000pg/mL. Urine was thawed to room temperature and 1mL of acetaminophen IS (20mg/mL in
ethanol) added to 1mL of urine followed by addition of 998mL of 0.1% formic acid. Twenty mL of an
aqueous creatinine standard or of a urine sample were injected onto a C18 column. Derivatization of
TMA with ethyl bromoacetate [65_TD$DIFF]affects creatinine and therefore creatinine is measured subsequent to
the measurement of TMA and TMAO.
Preparation of calibration standards
TMA-TMAO calibration standards were prepared in a similar fashion to aqueous standards, except
that 20mL of each TMA-TMAO working standard was added to 5mL of mouse urine instead of water.
The amount of TMA and TMAO in each calibration standard is a sum of the amount of TMA-TMAO in
the working standard used and the endogenous amounts of TMA-TMAO in urine. Creatinine
calibration standards were prepared by adding 1mL of mouse urine to 16mL of each creatinine
working standard, followed by the addition of 1mL of acetaminophen (20mg/mL in ethanol) and
982mL 0.1% formic acid. The amount of creatinine in each calibration standard is a sum of the amount
of creatinine in the working standard used and the endogenous amount of creatinine in the urine
sample. To determine the endogenous amounts of TMA, TMAO and creatinine in samples of urine used
for the preparation of these calibration standards, a blank urine (unspiked) sample was also analyzed
by LC–MS along with calibration standards.
Preparation of quality control standards
Intra- and inter-day accuracies and precisions of quantiﬁcation were determined using quality
control (QC) standards (QCs) for TMA, TMAO and creatinine: (1) LLOQQC (Lowest Limit of
QuantiﬁcationQuality Control); (2) LQC (LowQuality Control); (3)MQC (MediumQuality Control) and
(4) HQC (High Quality Control). The four QCs for TMA-TMAOwere 15pg/mL (LLOQQC), 45 pg/mL (LQC),
400pg/mL (MQC) and 750pg/mL (HQC) and for creatinine were 4pg/mL (LLOQQC), 12pg/mL (LQC),
6400pg/mL (MQC) and 12000pg/mL (HQC).
Liquid chromatography mass spectrometry (LC–MS)
Capillary LC–MS (cap-LC–MS) analysis was performed using an Accela Thermo LC system (Thermo
Scientiﬁc, UK) comprised of an Accela autosampler, vacuum degasser and pump system. The LC eluate
was directed into the electrospray source, which was interfaced to a Finnigan linear ion trap LTQmass
spectrometer (Thermo Scientiﬁc, UK). Twenty mL of sample was injected through a 20-mL loop
connected to an ACE C18 column maintained at 30 C. The sample tray temperature was kept at 4 C.
Themobile phaseswere 5mMammonium formate buffer, pH 6.0, inwater (mobile phase A) and 5mM
ammonium formate buffer, pH 6.0, in 90% acetonitrile (mobile phase B). Buffers were adjusted with
formic acid to pH 6, ﬁltered through 0.22-mm nylon membrane, degassed and stored at ambient
temperature. LC was performed at a ﬂow rate of 200mL/min with gradient set up: 5% mobile phase A
and 95%mobile phase B, changed to 95%mobile phase A and 5%mobile phase B over a period of 5min.
The eluate was directed into the LTQ mass spectrometer, which was operated in a positive-ion ESI
mode, with seven scan events: full ESI scan followed by six selected ionmonitoring scans (SIMs) over a
5-min LC run time. The ESI source was operated using the settings: spray voltage 4.5 kV, capillary
temperature 220 C, sheath gas 40 and auxiliary gas 10. Them/z rangewas scanned from50 to 200, and
centroid data were collected. SIMs were programmed to monitor derivatized-TMA (m/z 146) and
derivatized-2H9-TMA (m/z 155); TMAO (m/z 76) and 2H9-TMAO (m/z 85); creatinine (m/z 114) and
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microscans, each with a maximum injection time of 200ms.
Between each urine sample injection, 20mL of propan-2-ol: [66_TD$DIFF]methanol (1:1, v/v) was injected at
isocratic condition of 95% mobile phase B for a period of 5min. The injection needle was washed
5 times with 100mL of the same solvent. This was followed by 20mL 0.1% formic acid in methanol on
the C18 column using the LC gradient as for urine samples, to recondition the C18 column and to avoid
any carry over of sample to the next injection.
Data analysis
Data acquisition and processing was performed using Thermo Xcalibur Version 2.2 software
(Thermo Scientiﬁc, UK). Seven-point calibration curves were constructed for the concentration range
15–944pg/mL for TMA and TMAO and 3.9–16000pg/mL for creatinine, along with a blank urine
sample. Peak area ratios of analyte to its internal standard (IS) were calculated as a function ratio of
analyte concentration. Back calculations were performed from these curves to determine the
concentration of analytes. Calibration curves and lower and upper limits of quantiﬁcation (LLOQ or
ULOQ) were according to the FDA guidance [29].
Method validation
The method was validated for analyte separation, selectivity, sensitivity, limit of detection (LOD),
limit of quantiﬁcation (LOQ), carry-over effect, system suitability, accuracy, precision, dilution
integrity, ruggedness, robustness, matrix effect and stability as described in Supplementary data.
Calculations and statistics
Endogenous analyte concentrations in urine used to prepare the calibration standards were
determined and subtracted from the values determined in all the validationprotocols that used QCs, in
order to calculate the analyte concentration observed or recovered and to compare with the analyte
concentration added during the preparation of the standard. Unknown amounts of TMA, TMAO and
creatinine in mouse urine samples were quantiﬁed by reference to aqueous standard curves prepared
as described in Sections Preparation of standards and urine samples for TMA and TMAO analysis and
Preparation of standards and urine samples for creatinine analysis. Results are reported as
mean standard error of the mean. P <0.05 was selected for statistical signiﬁcance. Statistical
analyses were performed with GraphPad Prism Version 6.05 (GraphPad Software Inc., La Jolla, CA,
USA).
Chromatograms of analyte standards and TMA, TMAO and creatinine in mouse urine
ESI settings, LC separation and optimization are described in Supplementary data. Pure standards
of TMAO, 2H9-TMAO, derivatized TMA, derivatized-2H9-TMA, creatinine and acetaminophen [67_TD$DIFF]were
injected on the C18 column. Deuterium-labeled TMA and TMAO showed the same physico-chemical
properties as their light analogs when injected on the C18 column. Reconstructed-ion chromatograms
(RICs) for SIMs atm/z 76, 85,146155,114 and 152 showed chromatographic peaks at retention times of
1.97, 1.95, 3.27, 3.27, 1.96 and 2.51min, corresponding to TMAO, 2H9-TMAO, derivatized-TMA,
derivatized-2H9-TMA, creatinine and acetaminophen, respectively (Fig. 1A–F).
Mouse urine contains endogenous TMA, TMAO and creatinine. When unspiked mouse urine was
analyzed, RICs for SIMs atm/z 76, 146 and 114 showed three chromatographic peaks at 2.00, 3.27, and
1.94min, corresponding to the retention times of TMAO, derivatized TMA and creatinine (Fig. 1G, I, K).
As expected RICs for SIMs at m/z 85, 155, 152, corresponding to 2H9-TMAO, 2H9-TMA and
acetaminophen, did not generate chromatographic peaks in mouse urine (Fig. 1H, J, L). RIC
chromatograms for SIMs atm/z 76,146 and 114 of the urine samples and the pure standards generated
chromatographic peaks with the same retention times. Urine samples from both male and female
micewere analyzed from two strains, C57BL/6J and CD-1. Samples collected in themorning (C57BL/6J:
[(Fig._1)TD$FIG]
Fig.1. Reconstructed [41_TD$DIFF]ion chromatograms (RICs) for pure standards (A-F), urine (G-L) and urine spikedwith standards (M-R). RIC
of SIM at m/z 76, corresponding to TMAO (A); RIC [42_TD$DIFF]of SIM at m/z 85, corresponding to 2H9-TMAO (B); RIC of SIM at m/z 146,
corresponding to derivatized TMA (C); RIC of SIM atm/z 155, corresponding to derivatized-2H9-TMA (D); RIC of SIM atm/z 114,
corresponding to creatinine (E); RIC of SIM at m/z 152, corresponding to acetaminophen (F). RICs of urine for SIMs at m/z 76,
endogenous TMAO ( [43_TD$DIFF]G), m/z 146, endogenous derivatized TMA ( [44_TD$DIFF] ) and m/z 114, endogenous creatinine ( [45_TD$DIFF]K); and RICs of a urine
sample spikedwith TMAO, 2H9-TMAO, TMA, 2H9-TMA, creatinine and acetaminophen for SIMs atm/z 76 ([46_TD$DIFF]M),m/z 85 (N),m/z 146
(O), m/z 155 (P), m/z 114 (Q) and m/z 152 (R), respectively.
S. Veeravalli et al. /MethodsX 4 (2017) 310–319 315male, n =5, female, n =5; CD-1: male, n = 5, female, n = 6) and afternoon (C57BL/6J: male, n = 5, female,
n = 5; CD-1: male, n = 5, female, n = 6) were analyzed for each mouse. No signiﬁcant interfering
chromatographic peaks or co-eluting chromatographic peaks at the retention times corresponding to
derivatized TMA, TMAO and creatinine were present in any of the urine samples. Mouse urine spiked
with standards, RICs for SIMs at m/z 76, 85, 146, 155, 114 and 152 showed chromatographic peaks at
retention times of 2.02, 1.98, 3.27, 3.23, 1.93 and 2.77min, corresponding to TMAO, 2H9-TMAO,
derivatized-TMA, derivatized-2H9-TMA, creatinine and acetaminophen, respectively (Fig. 1M–R).
The chromatographic separation, together with SIM mass detection, gave an increased selectivity
and sensitivity for the analysis of derivatized TMA, TMAO and creatinine and their isotope-labeled and
IS analogs, suggesting there are no other endogenous interfering components in the urine samples.
Therefore, the established LC-SIMs method has speciﬁcity and selectivity for the determination of
TMA, TMAO and creatinine in mouse urine.
Our method does not require sample pre-treatment, such as solid-phase extraction. Despite the
absence of this step there was no evidence of urine metabolites interfering with the quantiﬁcation of
TMA, TMAO or creatinine. The separation step on the C18 column and the selectivity of the MS using
SIMs obviates the need for sample clean-up.
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Table 1 lists the measured linearity of the calibration curves for TMA (15–944pg/mL), TMAO (15–
944pg/mL) and creatinine (3.9–16000pg/mL). Because endogenous TMA, TMAO and creatinine were
detected in all mouse urine samples, 2H9-TMA, 2H9-TMAO and acetaminophen were chosen as the
appropriate IS for the cap-LC-SIMs analysis. In this way, the inﬂuence of endogenous TMA, TMAO and
creatinine on accurate quantiﬁcationwas minimized. Correlation coefﬁcients (R2) of linear regression
were 0.991 for all analytes in urine matrix, indicating a good quantitative relationship between the
MS responses and the analyte concentrations. Using ﬁve replicates of standards, the accuracy was
estimated as 92.36–103.46% and the precision was in the range 0.71–10.53%. Since no blank matrix
mouse urine sample exists that is free of endogenous TMA, TMAO and creatinine, water, which is non-
matrix solution, was used as a substitute matrix in preparing the aqueous standard curve (Table 1).
The curves demonstrated good linearity and, therefore, were used to quantify TMA, TMAO and
creatinine in urine.
The LOD and LOQ values shown in Table 1 are the on-column concentrations of TMA, TMAO and
creatinine. All analytes showed dynamic range of >1000 for the MS response, which covered the
biological concentration ranges for all analytes detected in mouse urine.
Assay accuracy and precision
To determine the accuracy of quantiﬁcation, the analytical recoveries were measured by cap-LC-
SIMs using the IS compound spiking-in approach for TMA, TMAO and creatinine. Intra-day accuracy
was evaluated from six analytical replicates prepared and analyzed by LC–MS. Table 2 shows the
analytical recovery of TMA, TMAO and creatinine. All intra-day recoveries were between 96.49% and
105.65%. The precision of quantiﬁcation was evaluated as coefﬁcients of variation (CVs) between the
samples. Intra-day precision was within 6.69%. Inter-day accuracy and precision was evaluated from
six analytical replicates prepared and analyzed by LC–MS on four different days. Table 2 shows the
inter-day accuracy was between 95.73% and 104.64% and precision was within 6.18%.
Validation of analyte carry-over effect, system suitability, dilution integrity, ruggedness,
robustness, matrix effect and stability are as described in Supplementary data.
Biological data
The concentrations of TMA and TMAO were normalized to that of creatinine, to account for any
variations in the concentration of urine. FMO3 is the protein that converts TMA to TMAO in the liver.
The expression of Fmo3 is under the control of sex steroids [32]. In male mice, the expression of the
Fmo3 gene is switched off [68_TD$DIFF]in liver at 6 weeks of age [33,34]. The consequent lack of FMO3 activity in
the liver of 10-week-old male mice is reﬂected in the data presented in Table 3. Male mice of both
strains analyzed excrete in the morning 5.5 (C57BL/6J) and 4 (CD-1) times as much TMA (mM)/
creatinine (mM) than do female mice. Conversely, female mice, which continue to express the Fmo3
gene into adulthood, excrete approximately 4 times more TMAO (mM)/creatinine (mM) than do adultTable 1
Limit of Detection (LOD), Limit of Quantiﬁcation (LOQ) and linearity by cap-LC-ESI-MS-SIMs after alkylation of TMA.
Compound LOD LOQ Aqueous Standards Mouse Urine
Linearity (As/
Ai)
SD of
slope
R2 [47_TD$DIFF] Linearity (As/Ai) SD of
slope
SD of
Intercept
R2 [48_TD$DIFF]
TMA 28pg/
mL
84pg/
mL
0.01737C 0.000193 0.9992 0.01708C+0.9454 0.000265 0.0279 0.9991
TMAO 115pg/
mL
345pg/
mL
0.00173C 0.000051 0.9999 0.00194C+0.0081 0.000057 0.0051 0.9975
Creatinine 1ng/mL 3ng/mL 0.00023C 0.000020 0.9996 0.00019C+0.0891 0.000018 0.0075 0.9910
As/Ai: peak area ratio of an analyte to the IS; C: concentration in pg/mL; SD: Standard Deviation.
Table 3
Concentrations of TMA and TMAO in urine collected at different times of day from male and female C57BL/6J and CD-1 mice.
C57BL/6J CD1
Morning Afternoon Morning Afternoon
TMA (mM)/Creatinine (mM) Male 3.0950.519 0.6230.065 (^^) 0.4040.037 (&&&) 0.7030.077 (^^)[49_TD$DIFF]
Female 0.552 0.066 (**) 0.2250.036
(***/^^)
0.1040.006
(****/&&&&)
[50_TD$DIFF]
0.0740.013
(****/&&)
[51_TD$DIFF]
TMAO (mM)/Creatinine
(mM)
Male 0.7040.030 0.1700.007 (^^^^) 0.1800.015 (&&&&) 0.1660.013
[52_TD$DIFF] emale 2.7290.201
(****)
1.3380.285
(**/^^)
0.6570.059
(****/&&&&)
[50_TD$DIFF]
0.4830.091 (*/&)
TMAO:TMA Male 0.2470.042 0.2800.024 0.4530.041 (&) 0.2500.034 (^^)
Female 5.0640.471
(****)
5.8650.455 (****) 6.3020.249 (****/&) 6.5190.302 (****)
Values aremean SEM, n =5–6. As indicated, signiﬁcant differences were observed betweenmale and female mice of the same
strain at the same time of day (*), morning and afternoon for mice of the same strain and sex (^) and different mouse strains of
the same sex and at the same time of day (&). * = p <0.05, ** =p< [53_TD$DIFF]*** = p<0.001, 0.01, **** =p<0.0001, ^^ =p<0.01,
^^^^ =p<0.0001, & =p<0.05, &&=p<0.01, &&&=p<0.001, and &&&&=p<0.0001.
Table 2
Intra- and inter-day reproducibility and accuracy of LC-ESI-SIMs analysis for TMA, TMAO and creatinine.
Analyte QC ID Added
Concentration
(pg/ml)
Intra-day Inter-day
n Observed
Concentration (pg/
ml) (Mean SD)
%
Accuracy
%CV n Observed
Concentration (pg/
ml) (Mean SD)
%
Accuracy
%CV
TMA LLOQQC 15 6 15.480.50 103.24 3.25 24 14.850.38 99.05 2.58
LQC 45 44.480.37 98.86 0.85 46.140.79 102.54 1.72
MQC 400 407.369.44 101.84 2.32 391.6711.97 97.92 3.06
HQC 750 723.6723.34 96.49 3.23 759.0523.06 101.21 3.04
TMAO LLOQQC 15 6 14.910.33 99.44 2.23 24 15.690.97 104.64 6.18
LQC 45 45.983.07 102.18 6.69 45.830.56 101.85 1.23
MQC 400 387.294.54 96.82 1.17 382.9216.38 95.73 4.28
HQC 750 756.1523.50 100.82 3.11 770.8514.39 102.78 1.87
Creatinine LLOQQC 4 6 4.220.19 105.65 4.55 24 3.910.11 97.87 2.91
LQC 12 11.950.11 99.63 0.99 11.860.21 99.13 1.79
MQC 6400 6536.96102.09 102.14 1.56 6447.36151.07 100.74 2.34
HQC 12000 11582.40262.21 96.52 2.26 12402.19187.25 103.35 1.51
S. Veeravalli et al. /MethodsX 4 (2017) 310–319 317males. The total TMA, i.e., TMA+TMAO, excreted is very similar in male and female mice from the
same strain. However, C57BL/6J mice excrete far greater amounts than do CD-1 mice of TMA (mM)/
creatinine (mM) (male) and TMAO (mM)/creatinine (mM) (female).
Our results demonstrate that the design of biological experiments reliant on the use of urinary TMA
or TMAO as biomarkers in mouse models must consider gender, strain and the time of day urine
samples are collected. The method described would also be suitable for quantiﬁcation of TMA, TMAO
and creatinine in clinical studies, including diagnosis of the disorder trimethylaminuria.
Conclusion
We have developed a sensitive method, combining chemical derivatization with ethyl
bromoacetate and cap LC-SIMs, for the targeted analysis of TMA, TMAO and creatinine and their
IS in mouse urine. All analyte identiﬁcation was achieved based on chromatographic separation with
318 S. Veeravalli et al. /MethodsX 4 (2017) 310–319uniquem/z values. The cap LC–SIMswas used for accurate quantiﬁcation andwe also performed scans
for structural conﬁrmation of the analytes. The method obviates the need for extra puriﬁcation steps
and allows all three analytes to be quantiﬁed rapidly (within 5min) in a urine volume as small as 6mL.
The selectivity, sensitivity, precision, accuracy, robustness and reproducibility of the method
demonstrate that it is well suited for quantiﬁcation of TMA, TMAO and creatinine, particularly in cases
where sample volume is limited, such as the urine of mice, a species that is often used in research and
preclinical studies. The results demonstrate that the design of biological experiments reliant on the
use of TMA or TMAO as biomarkers in mouse models must consider gender, strain and the time of day
urine samples are collected. The method would also be suitable for quantiﬁcation of TMA, TMAO and
creatinine in clinical studies, including diagnosis of the disorder trimethylaminuria.
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